Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SPR | P35270 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31087189 | 0.78 | MAPT (0.50) | HPGDBCHEMAPTPKML3MBTL1 | |
| SCHEMBL31087172 | 0.75 | HPGD (0.56) | HPGDBCHEMAPTLMNAPKM | |
| SCHEMBL609127 | 0.74 | BCHE (0.47) | BCHEMAPTL3MBTL1STK17BSTK17A | |
| SCHEMBL31087188 | 0.72 | HPGD (0.59) | HPGDMAPTLMNAPKML3MBTL1 | |
| SCHEMBL31087181 | 0.71 | MAPT (0.49) | HPGDBCHEMAPTLMNAPKM | |
| SCHEMBL31436060 | 0.70 | STK17B (0.58) | BCHELMNASTK17BSTK17A | |
| SCHEMBL1251130 | 0.70 | PARP1 (0.51) | — | |
| SCHEMBL569251 | 0.68 | TDP1 (0.74) | STK17BSTK17A | |
| SCHEMBL4640990 | 0.68 | BCHE (0.87) | BCHELMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL1252631 | 0.67 | PARP1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307394-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307394-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | MRGPRX1, MRGPRX4, MRGPRX2 | HPGD 831/4885SPR 1401/4885BCHE 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.